Locally Recurrent and Metastatic Breast Cancer
4
0
0
3
Key Insights
Highlights
Success Rate
75% trial completion
Treatment Research
12 treatments under study, led by Paclitaxel
Related Conditions
Often studied with 9 related conditions
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 87/100
25.0%
1 terminated out of 4 trials
75.0%
-11.6% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 3 completed trials
Clinical Trials (4)
Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer
Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients
A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast Cancer
Phase1b to Evaluate Safety of AMG706 in Combination With Paclitaxel or Docetaxel for Breast Cancer
Research Network
Common Treatments
- Paclitaxel3
- Bevacizumab2
- Motesanib Diphosphate1
- Amg 386 10 Mgkg Capecitabine And Lapatinib1
- Amg 7061
Active Sponsors
- Amgen4
Related Conditions
- Breast Cancer2
- Breast Neoplasms2
- Breast Tumors2
- Oncology1
- Tumors1